DrugPatentWatch Database Preview

Details for Patent: 10,478,439

« Back to Dashboard

Which drugs does patent 10,478,439 protect, and when does it expire?

Patent 10,478,439 protects IMBRUVICA and is included in two NDAs.

This patent has forty patent family members in seventeen countries.

Summary for Patent: 10,478,439

Title:	Use of inhibitors of bruton's tyrosine kinase (Btk)
Abstract:	Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Loury; David J. (Incline Village, NV)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	15/965,114
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,478,439
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,478,439

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF MANTLE CELL LYMPHOMA

International Family Members for US Patent 10,478,439

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011261185
Australia	2015275321
Australia	2018204179
Australia	2020202752
Brazil	112012030625